Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.60
Ask: 3.70
Change: -0.10 (-2.67%)
Spread: 0.10 (2.778%)
Open: 3.75
High: 3.75
Low: 3.65
Prev. Close: 3.75
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Sondrel wins USD23 million contract

Tue, 27th Feb 2024 14:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Signs an exploration agreement for the acquisition of its proprietary database of lithium targets in Texas. Smackover Resources LLC, a wholly owned subsidiary of Lonestar Lithium Inc, has purchased the proprietary database with regional modelling and data compilation across eastern Texas from Cloudbreak. The terms include: 2.0 million shares in Lonestar; USD25,000 each time a Qualifying Transaction property is generated from the database; and 0.5% Royalty produced lithium on each Qualifying Transaction property. The areement is for three years. Interim Chief Executive Andrew Male says: "This Exploration Agreement is a good example of the type of transactions Cloudbreak has completed in the past and will continue to do with a sector of its asset base. It took considerable time and effort to compile this database and being able to sell this on to Lonestar demonstrates the possible valuation accretion by doing this type of business."

----------

United Oil & Gas PLC - Oil and gas company, focused on Egypt, the UK and Jamaica - Raises GBP1.0 million through oversubscribed placing of 457.5 million shares and 42.5 shares by way of a subscription. A total of 500.0 million shares will be issued through the fundraising, 76% of the company's issued share capital. Funds will be used to progress work in Jamaica and for administration costs.

----------

Diaceutics PLC - Belfast-based provider of diagnostic commercialisation services to pharmaceutical and biotechnology companies - Expands its data supply network, which it says will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the UK. Jordan Clark, chief data officer of Diaceutics, comments: "This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."

----------

Crossword Cybersecurity PLC - London-based cybersecurity solutions provider - Launches Trillion HarVista. Says the Trillion HarVista tool allows enterprise security teams to search conversations on the dark web in a clean and sanitised environment. It "enables security teams, for the first time, to be able to identify the threats developing both from hacker discussions and shared compromised credential data all from a single interface, without the risk of searches on hostile websites being linked to your organisation."

----------

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Receives a first purchase order under the master services agreement with an unnamed "leading diagnostics company." The first purchase order, valued at around GBP60,000, has been received for an initial project to generate antibodies specifically for the client's use in diagnostic products. It is anticipated that further purchase orders will follow for additional and recurring projects. CEO Adrian Kinkaid says: "Reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies' technologies and capabilities. In this case it is the generation of antibodies in diagnostics products. We look forward to establishing a long-term relationship with our new partner and providing them with assistance to generate better antibodies which are more manufacturable and can be rapidly deployed in clinical diagnostic products for the benefit patient well-being across the globe."

----------

Sondrel Holdings PLC - Reading, England-based semiconductor design services firm - Wins new design and supply contract for a next generation video processing chip with a total estimated value of USD23 million across the design, qualification and projected production life of the product. "The complex chip is to be used for high performance professional video streaming solutions. The company has entered into the master agreement with the customer and design work has commenced whilst the parties finalise negotiations to the exhibits to the agreement," it says. The initial contract value is for over USD9 million for the duration of the design and qualification phases and the work will be fully funded by the customer. CEO Graham Curren says: "This is a substantial design and supply contract for Sondrel and a demonstration of the group's ability to provide the most complex engineering expertise required for these next generation technologies. We're delighted to partner with one of the leading manufacturers in the high growth video streaming market, where the constant innovation and focus on efficiency is driving demand for complex chips like Sondrel's." Also reports that it has received four new orders in 2024 year to date for its design consulting services, engaging with two existing customers and two new customers. These contracts will generate a combined revenue of USD900,000 in the current financial year.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Apr 2024 13:29

Fusion Antibodies inks commercial contract for OptiPhage library

(Alliance News) - Fusion Antibodies PLC on Monday said that it has signed a commercial contract to develop an OptiPhage library for a non-human antibody species.

Read more
27 Feb 2024 13:15

Fusion Antibodies gets first order under new services agreement

(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.

Read more
14 Feb 2024 12:52

Fusion Antibodies raises £1.38m as it seeks new customers

(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.

Read more
14 Feb 2024 11:27

IN BRIEF: Fusion Antibodies raises GBP1.4 million via placing

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Conditionally raises GBP1.4 million before expenses via placing of 34.4 million shares at 4 pence each. The issue price represents a discount of 5.9% to Fusion's closing mid-market share price on Tuesday. Further, it intends to issue 1.5 million new shares to certain directors in lieu of or in satisfaction of salary and fees due to them and which shall be issued immediately following publication of its announcement. Also intends to grant a total of up to 3.8 million new share options to staff and senior management.

Read more
6 Feb 2024 11:48

Fusion Antibodies strikes follow-on research and development project

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has won a follow-on project under a collaborative research and development agreement with an unnamed "US-based biotechnology company".

Read more
6 Feb 2024 10:05

AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
1 Feb 2024 16:27

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.

Read more
1 Feb 2024 12:00

Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform

(Alliance News) - Fusion Antibodies PLC on Thursday announced the receipt of a research & development tax credit from UK HM Revenue & Customs for work performed on the development of its OptiMAL platform and other projects in bioinformatics.

Read more
4 Dec 2023 16:56

LONDON MARKET CLOSE: FTSE 100 slips as miners hold down index

(Alliance News) - Stock prices in London closed lower on Monday, with miners and oil firms holding down the FTSE 100 index.

Read more
4 Dec 2023 12:01

Fusion Antibodies revenue falls, losses widen in first half

(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.

Read more
4 Dec 2023 10:23

AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
4 Dec 2023 10:22

Fusion Antibodies shares fall with revenue despite "positive" outlook

(Alliance News) - Fusion Antibodies PLC on Monday reported a widened loss and reduced revenue for its latest half year, but said its growth prospects are "increasingly positive".

Read more
28 Nov 2023 12:09

Fusion Antibodies shares up on deal with US National Cancer Institute

(Alliance News) - Fusion Antibodies PLC on Tuesday said it has signed a collaboration agreement with the US National Cancer Institute to use its OptiMAL product to discover novel antibodies to treat certain targets.

Read more
28 Nov 2023 10:33

AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.